CELMoDs for the treatment of newly diagnosed and HR smoldering MM

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase modulators (CELMoDs) in newly diagnosed multiple myeloma (NDMM) and high-risk smoldering multiple myeloma. During this interview, Richardson discusses the use of CELMoDs, particularly iberdomide, in earlier lines of therapy. Richardson reviews…